North America Vascular Stents Market Size, Share, and Growth Forecast 2026 - 2033

The North America vascular stents market is expected to be valued at US$ 6.8 billion in 2026 and is projected to reach US$ 10.2 billion, expanding at a CAGR of 6.0% between The rising prevalence of cardiovascular and peripheral vascular diseases across the U.S. and Canada is driving demand for minimally invasive stent procedures. Increasing adoption of drug-eluting, bioabsorbable, and advanced vascular stent technologies is further supporting market growth. In addition, the expansion of interventional cardiology and vascular care facilities, favorable reimbursement frameworks, growing healthcare expenditure, and rising adoption of image-guided minimally invasive procedures are improving access to stent-based treatments.

The growing geriatric population and increasing prevalence of diabetes and obesity are also contributing to the need for vascular interventions across North America. Furthermore, increasing investments in advanced catheterization laboratories and the adoption of robotic and AI-assisted imaging technologies are enhancing procedural precision and treatment outcomes. The presence of major medical device manufacturers and continuous product development in coronary, peripheral, and neurovascular stents is further strengthening market growth.

Growing awareness of early diagnosis and treatment of vascular disorders is encouraging patients to seek timely interventional procedures, particularly for coronary and peripheral artery diseases. Additionally, the increasing shift toward outpatient and ambulatory vascular procedures is creating opportunities for stent manufacturers as healthcare providers seek cost-efficient treatment options with shorter recovery times.

Drivers - Rising Prevalence of Cardiovascular and Peripheral Vascular Diseases

The increasing prevalence of coronary artery disease (CAD), peripheral artery disease (PAD), and other vascular disorders across the U.S. and Canada is a major driver of the North America vascular stents market. An aging population, combined with rising rates of diabetes, hypertension, obesity, and other cardiovascular risk factors, is expanding the patient population requiring vascular interventions. The established use of percutaneous coronary intervention (PCI) and endovascular procedures is supporting consistent demand for coronary and peripheral vascular stents. In addition, advanced hospital infrastructure, high procedural volumes, and greater access to specialized cardiovascular care are strengthening the adoption of minimally invasive stent-based treatments across North America.

Increasing awareness of cardiovascular disease symptoms and the importance of early diagnosis is also encouraging patients to seek timely intervention. The growing availability of specialized cardiac and vascular centers is improving access to diagnostic imaging, catheter-based procedures, and post-procedure care. Furthermore, continued improvements in clinical pathways and multidisciplinary cardiovascular care are supporting the wider use of stent-based therapies across the region.

Continuous Technological Advancements in Drug-Eluting and Next-Generation Stents

Ongoing technological advancements in drug-eluting, bioabsorbable, peripheral, and neurovascular stents are supporting market growth. New-generation stent designs focus on improving deliverability, vessel compatibility, restenosis prevention, and long-term clinical outcomes. Increasing adoption of advanced imaging and image-guided interventions is also enabling physicians to perform complex vascular procedures with greater precision. Furthermore, continued product development and regulatory approvals in the U.S. are expanding the availability of innovative stent technologies, encouraging healthcare providers to adopt newer solutions.

Manufacturers are increasingly focusing on thinner struts, improved drug-release mechanisms, flexible delivery systems, and enhanced biocompatibility to address complex lesions and challenging anatomies. The integration of advanced imaging with catheter-based interventions is also helping physicians improve device placement and procedural accuracy. These innovations are expected to strengthen the clinical value proposition of newer vascular stent platforms and support replacement demand for older technologies.

Restraints - High Cost of Advanced Stent Technologies and Procedures

The high cost associated with advanced vascular stents, catheterization laboratory equipment, imaging technologies, and specialized interventional procedures remains a restraint in the market. Premium drug-eluting, bioabsorbable, neurovascular, and aortic stent technologies can increase overall treatment costs for healthcare providers and payers. Although the U.S. has established reimbursement pathways for many vascular interventions, variations in insurance coverage, patient cost-sharing, and reimbursement policies can influence procedure adoption. In Canada, differences in provincial healthcare budgets and procurement processes can also affect the availability and adoption of newer vascular technologies.

High capital requirements for maintaining catheterization laboratories and specialized vascular facilities can further limit technology upgrades among smaller healthcare institutions. Hospitals also face pressure to control procedure costs while maintaining access to advanced medical devices and specialized clinical expertise. These economic considerations slow the adoption of premium stent technologies when lower-cost alternatives provide clinically acceptable outcomes.

Risk of Restenosis and Long-Term Procedural Complications

The risk of in-stent restenosis, thrombosis, vascular injury, and other long-term complications remains a key challenge. Although drug-eluting and next-generation stents have improved clinical outcomes, certain high-risk patients, including those with diabetes, complex lesions, or extensive vascular disease, remain susceptible to complications or repeat interventions. The need for post-procedure monitoring, antiplatelet therapy, and follow-up imaging can further increase the overall treatment burden. These clinical considerations influence physician decisions regarding patient selection and the choice between stenting, medical management, and alternative revascularization procedures.

Patients with multiple comorbidities require more intensive monitoring following stent implantation, increasing healthcare resource utilization. In addition, concerns regarding device-related adverse events can influence physician preferences for specific stent platforms and treatment approaches. Continued post-market surveillance and clinical evaluation are therefore important for demonstrating the long-term safety and effectiveness of newer vascular stent technologies.

Opportunities - Rising Adoption of Neurovascular and Aortic Stent Technologies

The increasing use of minimally invasive neurovascular and endovascular procedures represents a significant opportunity in the North America vascular stents market. Growing adoption of flow-diverting and other neurovascular devices for intracranial aneurysms, along with the increasing use of aortic stent grafts for endovascular aneurysm repair (EVAR), is expanding the addressable market. Improvements in device flexibility, deployment accuracy, imaging guidance, and patient selection are enabling physicians to treat increasingly complex vascular conditions through catheter-based approaches. The presence of advanced neurovascular and vascular centers across the U.S. and Canada is expected to further support adoption.

The growing preference for less invasive alternatives to open vascular surgery is further supporting demand for these technologies. Increasing clinical experience with complex endovascular procedures is enabling physicians to treat a broader range of patients who previously have required surgical intervention. In addition, investments in hybrid operating rooms and advanced vascular imaging infrastructure are expected to create additional opportunities for neurovascular and aortic stent manufacturers.

Growing Demand for Bioabsorbable and Next-Generation Stent Technologies

Increasing investment in bioabsorbable materials, advanced drug-eluting platforms, and next-generation stent designs creates opportunities for manufacturers operating in North America. These technologies are being developed to improve vascular healing, reduce restenosis, and address limitations associated with permanent metallic implants. Continued R&D investment by medical device companies, clinical studies, and technological improvements in polymer and metallic materials are supporting innovation in this segment.

As healthcare providers increasingly focus on improving procedural outcomes and reducing the need for repeat interventions, demand for advanced stent technologies is expected to create new growth opportunities across the U.S. and Canada. The strong presence of leading medical device manufacturers and research institutions in the U.S. is supporting continued innovation and commercialization of advanced vascular devices. Increasing clinical research and product development activities are also creating opportunities to improve stent performance across coronary, peripheral, neurovascular, and aortic applications. Furthermore, the growing emphasis on personalized and outcome-oriented cardiovascular care is expected to encourage the adoption of technologies that provide improved long-term patient outcomes.

Product Type Insights

Coronary stents are the dominant product type segment, accounting for around 55.8% of the North America vascular stents market share in 2026. The segment's leadership is primarily driven by the high prevalence of coronary artery disease (CAD) across the U.S. and Canada, making coronary intervention one of the most frequently performed vascular procedures in the region. Percutaneous coronary intervention (PCI) remains an established minimally invasive approach for restoring blood flow in patients with obstructive coronary lesions, supporting consistent demand for coronary stents. Continuous advancements in drug-eluting stents, thinner strut designs, improved polymer coatings, and enhanced delivery systems have further improved procedural performance and clinical outcomes.

Leading medical device companies, including Abbott, Boston Scientific Corporation, Medtronic, and Terumo Corporation, continue to invest in next-generation coronary stent platforms, strengthening segment growth. The availability of advanced catheterization laboratories and experienced interventional cardiologists across major U.S. and Canadian healthcare centers is further supporting the adoption of coronary stents. In addition, increasing cardiovascular screening, growing procedural volumes among aging populations, and improvements in post-procedure care are expected to sustain demand throughout the forecast period.

Aortic stent grafts are the fastest-growing product type segment in the market, driven by the rising prevalence of abdominal and thoracic aortic aneurysms and increasing adoption of minimally invasive endovascular aneurysm repair procedures. Growing preference for shorter hospital stays, reduced surgical trauma, and improved patient recovery is further supporting demand for advanced aortic stent graft systems across the region.

Material Insights

Metallic stents are expected to lead the market with around 84.6% share in 2026, making them the dominant material segment. Their strong market position is supported by extensive clinical experience, high mechanical strength, excellent radial support, and established safety profiles across coronary, peripheral, neurovascular, and aortic applications. Advanced cobalt-chromium, platinum-chromium, and nitinol alloys provide improved flexibility, radiopacity, thinner strut profiles, and resistance to vessel recoil, making metallic stents suitable for a wide range of complex vascular procedures.

Ongoing innovations in drug-eluting coatings, alloy engineering, surface modification, and stent architecture continue to improve procedural outcomes while reducing risks such as restenosis and thrombosis. Although polymer-based and bioabsorbable technologies are gaining attention, metallic stents continue to dominate because of their established clinical performance, regulatory approvals, physician familiarity, and broad availability across North American healthcare facilities. Strong physician confidence and extensive clinical evidence further support the continued use of metallic stents in routine and complex interventions. Moreover, manufacturers are developing thinner and more flexible metallic platforms to improve vessel conformability and facilitate treatment of challenging anatomical conditions.

End-User Insights

Hospitals remain the leading end-user segment, capturing around 67.4% share of the North America vascular stents market in 2026. This dominance reflects hospitals' role as the primary centers for performing complex coronary, peripheral vascular, neurovascular, and aortic interventions requiring advanced catheterization laboratories and specialized clinical expertise. A significant proportion of vascular stenting procedures are conducted in hospital settings because of the availability of sophisticated imaging systems, hybrid operating rooms, emergency services, intensive care facilities, and multidisciplinary cardiovascular teams.

Hospitals are also equipped to manage emergency conditions such as acute myocardial infarction, ischemic stroke, and severe vascular complications that require immediate intervention. Furthermore, continued investments in cardiovascular infrastructure, expansion of specialized vascular centers, and increasing procedure volumes are reinforcing hospitals' dominant position in the region.

U.S. Vascular Stents Market Trends and Insights

The U.S. is expected to lead the North America vascular stents market by holding around 90.0% share in 2026. The country's dominance is supported by its highly developed interventional cardiology ecosystem, extensive network of hospitals and specialized cardiovascular centers, and high procedural volumes for coronary, peripheral, neurovascular, and aortic interventions. Strong healthcare expenditure, established reimbursement mechanisms, and continued regulatory approvals for innovative vascular devices are encouraging the adoption of advanced stent technologies.

The presence of major manufacturers such as Abbott, Boston Scientific, Medtronic, and Edwards Lifesciences is also supporting continuous product development and clinical innovation. Increasing adoption of minimally invasive procedures, advanced intravascular imaging, robotic-assisted interventions, and next-generation drug-eluting stents is expected to further strengthen market growth.

In addition, the growing elderly population and increasing prevalence of diabetes, obesity, and cardiovascular disease are expanding the addressable patient population. The expansion of ambulatory and outpatient vascular procedures is also creating opportunities for shorter-stay treatment models and improving healthcare resource utilization. Increasing investments in precision cardiovascular care, digital imaging technologies, and clinical research are expected to accelerate the development and adoption of innovative stent platforms in the U.S.

Canada Vascular Stents Market Trends and Insights

Canada accounts for around 10.0% of the North America vascular stents market revenue in 2026. Canada’s market is supported by an aging population, increasing prevalence of cardiovascular and peripheral vascular diseases, and continued investments in healthcare infrastructure. Canadian hospitals and cardiovascular centers are progressively expanding access to catheterization laboratories, advanced diagnostic imaging, and minimally invasive vascular procedures. The adoption of drug-eluting coronary stents, peripheral vascular stents, and endovascular technologies is increasing as healthcare providers focus on improving procedural outcomes and reducing recovery times.

Government-supported healthcare programs and investments in specialized cardiovascular services are improving access to vascular interventions across major healthcare networks. Furthermore, increasing collaboration between hospitals, academic institutions, and medical device companies is supporting clinical research and the adoption of innovative vascular technologies.

The modernization of cardiovascular facilities and increasing availability of specialized vascular care are expected to improve treatment access beyond major metropolitan areas. In addition, rising awareness of cardiovascular disease prevention and earlier diagnosis is likely to encourage timely intervention and support demand for vascular stent procedures in Canada.

The North America vascular stents market is moderately consolidated, with competition led by established multinational medical device manufacturers and supported by an expanding base of regional companies, particularly across Asia Pacific. Medtronic, Abbott, Boston Scientific Corporation, Terumo Corporation, and BIOTRONIK SE & Co. KG collectively account for a significant share of the competitive landscape, leveraging extensive product portfolios, strong global distribution networks, and continuous investment in research and development. These market leaders are focused on advancing next-generation drug-eluting, covered, and bioresorbable stent technologies to improve long-term clinical outcomes and strengthen their competitive positioning.

Strategic initiatives, including product launches, regulatory approvals, acquisitions, and collaborations with hospitals and research institutions, continue to expand their presence across coronary, peripheral, and neurovascular applications. Meanwhile, companies such as MicroPort Scientific Corporation, Meril Life Sciences Pvt. Ltd., Sahajanand Medical Technologies Ltd., Cordis, B. Braun SE, Cook Medical LLC, W. L. Gore & Associates, Inc., Biosensors International Group, Ltd., Lepu Medical Technology (Beijing) Co., Ltd., and iVascular S.L.U. are enhancing market competition through technological innovation, geographic expansion, and competitively priced product offerings tailored to the needs of both developed and emerging healthcare markets.

Key Industry Developments

• In May 2026, Boston Scientific Corporation received U.S. FDA approval for the TAXUS Liberte Atom Paclitaxel-Eluting Coronary Stent System, a next-generation drug-eluting stent for treating small coronary vessels. The approval expands the company's coronary intervention portfolio in the U.S.
• In October 2025, Medtronic expanded its carotid stent portfolio with the commercial launch of the Neuroguard IEP System, an integrated device combining a carotid stent, dilation balloon, and embolic protection filter to simplify carotid artery stenting procedures.